Sugi Predict

Sugi Predict / Compounds / SCHEMBL1815801

SCHEMBL1815801

SCHEMBL1815801

CCOC(=O)CCc1cc(OC)ccc1-c1ccc(-c2cccnc2)c(CF)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 10/20 0.43
▸ CYP11B1 P15538 9/20 0.43
▸ CYP17A1 P05093 4/20 0.43
▸ CCNC P24863 1/20 0.42
▸ CDK8 P49336 1/20 0.42
▸ MTNR1A P48039 1/20 0.42
▸ MTNR1B P49286 1/20 0.42
▸ CYP19A1 P11511 2/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ PTPN1 P18031 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ PPARG P37231 1/20 0.40
▸ TSHR P16473 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ CYP1A1 P04798 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1818457 0.91 CYP4F2 (0.46) CYP11B2CYP11B1CYP17A1CCNCCDK8
SCHEMBL1889329 0.90 CYP11B2 (0.49) CYP11B2CYP11B1CYP17A1CCNCCDK8
SCHEMBL1817206 0.88 CCNC (0.39) CYP11B2CYP11B1CYP17A1CCNCCDK8
SCHEMBL1805030 0.88 CYP11B2 (0.47) CYP11B2CYP11B1CYP17A1CCNCCDK8
SCHEMBL1812968 0.88 CYP11B2 (0.41) CYP11B2CYP11B1CYP17A1CCNCCDK8
SCHEMBL1821059 0.87 MTNR1A (0.46) MTNR1AMTNR1BPTPN1ALDH1A1PPARG
SCHEMBL1818710 0.87 CYP11B2 (0.42) CYP11B2CYP11B1CYP17A1CCNCCDK8
SCHEMBL19209436 0.86 XDH (0.46) CYP11B2CYP11B1CCNCCDK8MTNR1A
SCHEMBL1904414 0.84 MTNR1A (0.43) MTNR1AMTNR1BPTPN1KDM4EPPARG
SCHEMBL1804381 0.79 CYP4F2 (0.47) CYP11B2CYP11B1CCNCCDK8CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099533-A1 TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) WITH GPBP1 INHIBITORS UNIVERSITAT DE VALÈNCIA (ES) 2026-05-15 — — WO claimed
WO-2016107906-A1 METHODS FOR INHIBITING MESENCHYMAL PHENOTYPE AFTER EPITHELIAL-TO-MESENCHYMAL TRANSITION FIBROSTATIN, S.L. (ES) 2016-07-07 — — WO claimed
US-20160184274-A1 Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition UNIVERSITAT DE VALENCIA (ES) 2016-06-30 — — US claimed
US-9199936-B2 GPBP inhibition using Q2 peptidomimetics Fibrostatin Sociedad Limitada (ES) 2015-12-01 — — US claimed
EP-2496544-B1 GPBP INHIBITION USING Q2 PEPTIDOMIMETICS FIBROSTATIN S L (SE) 2014-08-20 — — EP claimed
US-20140080852-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2014-03-20 — — US claimed
EP-2496544-A1 GPBP INHIBITION USING Q2 PEPTIDOMIMETICS Fibrostatin, S.L. (SE) 2012-09-12 — — EP claimed
WO-2011054530-A1 GPBP INHIBITION USING Q2 PEPTIDOMIMETICS FIBROSTATIN, S.L. (ES) 2011-05-12 — — WO claimed
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2011-05-05 — — US claimed
WO-2026099533-A1 TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) WITH GPBP1 INHIBITORS UNIVERSITAT DE VALÈNCIA (ES) 2026-05-15 — — WO disclosed
US-10544083-B2 GPBP inhibition using Q2 peptidomimetics UNIVERSITAT DE VALÈNCIA (ES) 2020-01-28 — — US disclosed
US-10544083-B2 GPBP inhibition using Q2 peptidomimetics UNIVERSITAT DE VALÈNCIA (ES) 2020-01-28 — — US disclosed
US-20180179139-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2018-06-28 — — US disclosed
US-20180179139-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2018-06-28 — — US disclosed
US-8586776-B2 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2013-11-19 — — US disclosed
US-8586776-B2 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2013-11-19 — — US disclosed
WO-2011054530-A1 GPBP INHIBITION USING Q2 PEPTIDOMIMETICS FIBROSTATIN, S.L. (ES) 2011-05-12 — — WO disclosed
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2011-05-05 — — US disclosed
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2011-05-05 — — US disclosed
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2011-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544083-B2 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 CYP11B2 2503/4885CYP11B1 2299/4885CYP17A1 2866/4885
US-20140080852-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 CYP11B2 2503/4885CYP11B1 2299/4885CYP17A1 2866/4885
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 CYP11B2 2503/4885CYP11B1 2299/4885CYP17A1 2866/4885
US-20160184274-A1 Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition VIM, EPCAM, CDH1 CYP11B2 4800/4885CYP11B1 4835/4885CYP17A1 4359/4885
US-20180179139-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 CYP11B2 2503/4885CYP11B1 2299/4885CYP17A1 2866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.